Jul 31, 2021 · We appraised the impact of daratumumab (DARA)- and isatuximab (ISA)-based DFMT to crosslink CD38 receptors on CD38+ lymphoma (Raji, Daudi) and multiple myeloma cells (RPMI 8226, ANBL-6). The biological properties of DFMTs were determined by flow cytometry, confocal fluorescence microscopy, reactive oxygen species determination, lysosomal ...

Mar 6, 2024 · ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the...

Flow cytometry analysis confirmed dose-dependent binding of HexaBody-CD38 to cell lines expressing variable CD38 levels on the plasma membrane (Daudi (∼200,000 ABS/cell), Wien-133 (∼100,000 ABS/cell) and NALM-16 cells (∼50,000 ABS/cell)), with an overall average EC 50 in the subnanomolar range .

Jul 31, 2021 · Aiming to improve the efficacy of treatment of B cell malignancies in general and of multiple myeloma in particular, we evaluated the impact of crosslinking CD38 receptors on the mechanism and extent of apoptotic induction in four CD38 positive malignant B cells (Daudi, Raji, RPMI 8226, and ANBL-6).

Feb 1, 2011 · CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope.

Dec 6, 2014 · In this study, the efficacy of these anti-CD38 mAb was directly compared to DARA with respect to binding, apoptosis, CD38 ectoenzyme activity, and the induction of ADCC, ADCP and CDC.

Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma (MM) cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction.

Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as...

Feb 10, 2016 · Daratumumab (also referred to as HuMax-CD38 and IgG1-005) is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody (mAb) that specifically binds a unique epitope present on the CD38 molecule. Specific and strong binding of daratumumab to CD38 expressed on the cell surface on Daudi cells as well as fresh MM cells was shown 63.

Jul 1, 2021 · Daudi cells and MOLP-8 cells were phagocytosed by M2c macrophages by all three CD38 antibodies. However, LP-1 cells were relatively the most resistant to phagocytosis. Apoptosis was assessed in the presence and absence of Fc receptor (FcR) crosslinking.